Abstract: This invention is directed to oral-intestinal vaccines and their use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.

Abstract: This invention is directed to oral-intestinal vaccines and their use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.

Abstract: Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1–100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer as a blend of uncapped (free carboxyl end group) and end-capped forms ranging in ratios from 100/0 to 1/99.

Abstract: Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer having a molar composition of lactide/glycolide from 90/10 to 40/60, which may contain a pharmaceutically-acceptable adjuvant, as a blend of uncapped free carboxyl end group and end-capped forms ranging to ratios from 100/0 to 1/99.

Abstract: Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group, and end-capped forms ranging in ratios from 100/0 to 1/99.

Abstract: This invention relates to an immunostimulating composition comprising encapsulating microspheres, which may contain a pharmaceutically-acceptable adjuvant, wherein said microspheres having a diameter between 1 nanometer (nm) to 10 microns (um) are comprised of (a) a biodegradable-biocompatible poly(DL-lactide-co-glycolide) as the bulk matrix, wherein the relative ratio between the amount of lactide and glycolide components are within the range of 40:60 to 0:100 and wherein said poly (DL-lactide-co-glycolide) is present in an uncapped form and an end-capped form wherin a ratio of uncapped to end-capped forms is 99/1 to 1/99, and (b) an immunogenic substance comprising Colony Factor Antigen (CFA/II), hepatitis B surface antigen (HbsAg), or a physiologically similar antigen that serves to elicit the producton of antibodies in animal subjects. The preparation of its composition and its use as a vaccine is also disclosed.

Abstract: Assay methods for determining whether a peptide is likely to be immunogenic are based on a computer modeling of binding to a Class II MHC DR1 receptor. This is confirmed by competitive inhibition binding assays. The peptides are useful for eliciting an immune response for vaccination or the production of antibodies or T-cells.

Abstract: The invention provides Glutamine Transport ATP-Binding Protein polypeptides and DNA (RNA) encoding Glutamine Transport ATP-Binding Protein polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing Glutamine Transport ATP-Binding Protein polypeptides to screen for antibacterial compounds.

Abstract: Novel burst-free, sustained release biocompatible and biodegrable microcapsules which can be programmed to release their active core for variable durations ranging from 1-100 days in an aqueous physiological environment. The microcapsules are comprised of a core of polypeptide or other biologically active agent encapsulated in a matrix of poly(lactide/glycolide) copolymer, which may contain a pharmaceutically-acceptable adjuvant, as a blend of upcapped free carboxyl end group and end-capped forms ranging in ratios from 100/0 to 1/99.

Abstract: The invention provides era polypeptides and DNA (RNA) encoding era polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing era polypeptides to screen for antibacterial compounds.

Abstract: The invention provides era polypeptides and DNA (RNA) encoding era polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing era polypeptides to screen for antibacterial compounds.

Abstract: This invention relates to parenteral and mucosal vaccines against diseases aused by intracellular pathogens using antigens encapsulated within a biodegradable-biocompatible microspheres(matrix).

Abstract: A hybrid evaporation-extraction process for preparing microspheres of a p(DL-lactide-to-glycolide) biodegradable polymer, comprising:a. preparing a lyophilized biologically active material-sucrose matrix; adding acetonitrile solvent to biologically active material-sucrose matrix to form a solution;b. preparing a solution of a biodegradable poly (DL-lactide-co-glycolide) polymer by adding acetonitrile solvent to the polymer;c. adding the biodegradable poly (DL-lactide-co-glycolide) polymer acetonitrile solution to the biologically active material-sucrose acetonitrile solution;d. adding with stirring an oil containing lecithin to the poly (DL-lactide-co-glycolide) polymer-sucrose-biologically active material solution to evaporate acetonitrile and form an emulsion containing microspheres of poly (DL-lactide-co-glycolide) biodegradable polymers;e. adding the emulsion from step d. into a solvent selected from heptane, hexane, pentane or isopropanol; andf.

Abstract: In a solvent extraction process for preparing microspheres of a biodegrade polymer, the improvement comprising: preparing a homogenized antigen-sucrose matrix and adding a solvent to the sucrose-antigen matrix to form a solution; preparing a solution of a biodegradable polymer by adding a solvent to the polymer; adding the biodegradable polymer solution to the antigen-sucrose solution; adding an oil to the polymer-sucrose-antigen solution to form an emulsion having a controlled viscosity that corresponds to a predetermined average particle size of distributions of microspheres of biodegradable polymers; centrifuging the emulsion of controlled viscosity and removing the supernatant to obtain microspheres of a predetermined range of particle size distributions of from about 0.5 to about 7.0 micrometers.

Abstract: This invention is directed to oral parenteral and intestinal vaccines and eir use against diseases caused by enteropathogenic organisms using antigens encapsulated within biodegradable-biocompatible microspheres.

Abstract: It has now been determined that cancer cells have a specific surface protein existing as a glycoprotein which functions to stimulate specific cell-mediated immune response in the host directed toward the specific cancer. The following disclosure includes the method of identification of the specific cell surface protein and procedures utilizing the protein, or preferably the active peptide in testing for specific cancers and immunization. Having identified the specific cell surface protein for a cancer, the n-terminal tridecapeptide or the active portion of the peptide may be synthesized and utilized in testing and immunization. Further, the specific cell surface protein and active peptide for ductal carcinoma (brest cancer) is identified herein.

Abstract: A fishing lure exhibiting a combined traversing action and spray inducing surfing has a streamlined body with a flat top and a trailing flexible skirt. The body is diamond shaped in one cross-section and has a leader receiving aperture extending longitudinally therethrough. A long cylindrical weight is positioned symmetrically between the body sides and eccentrically between the flat top and leader receiving aperture.

Abstract: This invention relates to parenteral and mucosal vaccines against diseases caused by intercellular pathogens using antigens encapsulated within a biodegradable-biocompatible microspheres(matrix).

Abstract: In a solvent extraction process for preparing microspheres of a biodegradable polymer, the improvement comprising: preparing a homogenized antigen-sucrose matrix and adding a solvent to the sucrose-antigen matrix to form a solution; preparing a solution of a biodegradable polymer by adding a solvent to the polymer; adding the biodegradable polymer solution to the antigen-sucrose solution; adding an oil to the polymer-sucrose-antigen solution to form an emulsion having a controlled viscosity that corresponds to a predetermined average particle size of distributions of microspheres of biodegradable polymers; centrifuging the emulsion of controlled viscosity and removing the supernatant to obtain microspheres of a predetermined range of particle size distributions of from about 0.5 to about 7.0 micrometers.